Candriam S.C.A. Lowers Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Candriam S.C.A. lowered its stake in BioNTech SE (NASDAQ:BNTX) by 8.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 846,934 shares of the company’s stock after selling 80,230 shares during the period. Candriam S.C.A.’s holdings in BioNTech were worth $96,508,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of BNTX. Bank of New York Mellon Corp boosted its position in BioNTech by 4.3% during the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock valued at $419,000 after acquiring an additional 150 shares in the last quarter. Perigon Wealth Management LLC increased its stake in BioNTech by 3.9% in the 4th quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company’s stock worth $666,000 after buying an additional 224 shares in the last quarter. Atomi Financial Group Inc. increased its stake in BioNTech by 6.7% in the 4th quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company’s stock worth $414,000 after buying an additional 229 shares in the last quarter. Jones Financial Companies Lllp grew its position in shares of BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after purchasing an additional 246 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after acquiring an additional 300 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $114.77 on Thursday. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The firm has a 50-day moving average of $117.07 and a two-hundred day moving average of $112.47. The company has a market capitalization of $27.51 billion, a price-to-earnings ratio of -54.65 and a beta of 0.30. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BNTX. HC Wainwright reissued a “buy” rating and issued a $150.00 price objective on shares of BioNTech in a research note on Monday, November 18th. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. Truist Financial began coverage on shares of BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 price target on the stock. JPMorgan Chase & Co. dropped their price objective on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a report on Tuesday, November 26th. Finally, BMO Capital Markets reissued an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $142.72.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.